Tumour mutational burden is overestimated by target cancer gene panels
Background: Tumour mutational burden (TMB) has emerged as a predictive marker for responsiveness to immune checkpoint inhibitors (ICI) in multiple tumour types. It can be calculated from somatic mutations detected from whole exome or targeted panel sequencing data. As mutations are unevenly distribu...
Main Authors: | , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2023-03-01
|
Series: | Journal of the National Cancer Center |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2667005422000801 |